Abatacept
- Generic Name
- Abatacept
- Brand Names
- Orencia
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 332348-12-6
- Unique Ingredient Identifier
- 7D0YB67S97
- Background
Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of tw...
- Indication
Abatacept is indicated in adult patients for the treatment of moderately-to-severely active rheumatoid arthritis and for the treatment of active psoriatic arthritis. In patients two years of age and older, abatacept is also indicated for the treatment of moderately-to-severely active juvenile idiopathic arthritis.
...
- Associated Conditions
- Acute Graft-Versus-Host Disease (GVHD), Moderate to Severe Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Polyarticular juvenile rheumatoid arthritis, chronic or unspecified, Psoriatic Arthritis
- Associated Therapies
- -
Patient-Reported Efficacy of Subcutaneous (SC) Abatacept in Rheumatoid Arthritis (RA) - South Africa
- First Posted Date
- 2015-11-06
- Last Posted Date
- 2016-02-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 69
- Registration Number
- NCT02598466
Abatacept in Juvenile Dermatomyositis
- First Posted Date
- 2015-11-03
- Last Posted Date
- 2022-08-29
- Lead Sponsor
- George Washington University
- Target Recruit Count
- 10
- Registration Number
- NCT02594735
- Locations
- 🇺🇸
2300 M Street, 9th floor. Medical Faculty Associates, The George Washington University., Washington, District of Columbia, United States
Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)
- Conditions
- Interventions
- First Posted Date
- 2015-10-30
- Last Posted Date
- 2021-03-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 36
- Registration Number
- NCT02592798
- Locations
- 🇺🇸
Levine Children's Hospital, Charlotte, North Carolina, United States
🇺🇸Children's National Health System, Washington, District of Columbia, United States
🇺🇸Columbia University Medical Center (Cumc), New York, New York, United States
Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2015-09-23
- Last Posted Date
- 2020-09-03
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 80
- Registration Number
- NCT02557100
- Locations
- 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
🇲🇽Clinica de Investigacion en Reumatologia y Obesidad S.C., Guadalajara, Jalisco, Mexico
🇲🇽Clinica Integral en Osteoporosis y Artritis CLINOSAR Mexico S.A. de C.V., Mexico D.F., Mexico
Vaccination Against Pneumococcal in Naïve Abatacept Rheumatoid Arthritis Patients
- Conditions
- Interventions
- First Posted Date
- 2015-09-11
- Last Posted Date
- 2022-01-03
- Lead Sponsor
- University Hospital, Montpellier
- Target Recruit Count
- 80
- Registration Number
- NCT02547493
- Locations
- 🇫🇷
CHU Nord, Amiens, France
🇫🇷CHRU de Montpellier, Montpellier, Hérault, France
🇫🇷CHU Pellegrin, Bordeaux, France
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2015-07-21
- Last Posted Date
- 2021-06-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 994
- Registration Number
- NCT02504268
- Locations
- 🇺🇸
Arizona Arthritis & Rheumatology Research PLLC, Sun City, Arizona, United States
🇺🇸Rheumatology Associates Of North Alabama, P.C., Huntsville, Alabama, United States
🇺🇸CHI St. Vincent Medical Group Hot Springs, Hot Springs, Arkansas, United States
Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept
- Conditions
- Interventions
- First Posted Date
- 2015-02-03
- Last Posted Date
- 2020-10-01
- Lead Sponsor
- Dr. Larry W. Moreland
- Target Recruit Count
- 10
- Registration Number
- NCT02353780
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Open-label Pilot Study of Abatacept for the Treatment of Vitiligo
- First Posted Date
- 2014-11-02
- Last Posted Date
- 2017-08-09
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT02281058
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation
- First Posted Date
- 2014-09-05
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 1
- Registration Number
- NCT02232880
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Post-marketing Study Assessing the Long-Term Safety of Abatacept
- First Posted Date
- 2014-06-23
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 100000
- Registration Number
- NCT02169544
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.